½ÃÀ庸°í¼­
»óǰÄÚµå
1593929

¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå : À¯Çü, ¾àÁ¦, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Malaria Vaccine Market by Type (Erythrocytic Vaccine, Multi-Antigen Vaccine, Pre-Erythrocytic Vaccine), Agent (Anopheles Species, Plasmodium Falciparum, Plasmodium Vivax), End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 194 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¸»¶ó¸®¾Æ ¹é½Å ½ÃÀåÀÇ 2023³â ½ÃÀå ±Ô¸ð´Â 6,434¸¸ ´Þ·¯·Î, 2024³â¿¡´Â 8,088¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 25.78%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 3¾ï 2,066¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸»¶ó¸®¾Æ ¹é½Å ½ÃÀåÀº ƯÈ÷ ¾ÆÇÁ¸®Ä«, µ¿³²¾Æ½Ã¾Æ, ¶óƾ¾Æ¸Þ¸®Ä« ÀϺΠÁö¿ªÀ» Áß½ÉÀ¸·Î ¸»¶ó¸®¾Æ°¡ À¯ÇàÇÏ´Â Áö¿ª¿¡¼­ ¸»¶ó¸®¾Æ ÅðÄ¡¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â °ÍÀ¸·Î Á¤Àǵ˴ϴÙ. ¸»¶ó¸®¾Æ ¹é½ÅÀÇ Çʿ伺Àº ¸»¶ó¸®¾Æ°¡ ½É°¢ÇÑ ÀÌȯÀ²°ú »ç¸Á·üÀ» ÃÊ·¡Çϰí Àü ¼¼°è¿¡¼­ Áö¼ÓÀûÀÎ °Ç°­ ¹®Á¦¸¦ ¾ß±âÇϰí ÀÖÀ¸¹Ç·Î ´õ¿í °­Á¶µÇ°í ÀÖ½À´Ï´Ù. ¸»¶ó¸®¾Æ ¹é½ÅÀÇ ÁÖ¿ä ¿ëµµ´Â °¨¿°·ü°ú ÀüÆÄ¸¦ ÁÙÀ̱â À§ÇÑ ¿¹¹æÁ¢Á¾À¸·Î, °¨¿°µÈ Áö¿ªÀÇ °øÁߺ¸°ÇÀ» °³¼±ÇÏ°í °æÁ¦ »ý»ê¼ºÀ» Çâ»ó½ÃŰ´Â µ¥ ±â¿©ÇÕ´Ï´Ù. ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚ¿¡´Â Á¤ºÎ º¸°Ç ±â°ü, ºñÁ¤ºÎ±â±¸, °øÁß º¸°Ç ±¸»ó, ¹Î°£ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ Æ÷ÇԵǸç, À¯Åë ±Ô¸ð´Â ¹Î°£ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ Æ÷ÇԵ˴ϴÙ. ½ÃÀå ÀλçÀÌÆ®¿¡ µû¸£¸é R&D ÅõÀÚ Áõ°¡, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ¹ßÀü, ¼¼°è º¸°Ç ÆÄÆ®³Ê½Ê µîÀÇ ¿äÀÎÀÌ ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÃÖ±Ù WHOÀÇ RTS, S/AS01(¸ð½ºÅ°¸¯½º) ¹é½ÅÀÇ ½ÂÀÎÀº ´ë±Ô¸ð ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥À¸·Î È®´ëµÉ ¼ö ÀÖ´Â ÁÁÀº ±âȸ·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ È¿°úÀûÀ¸·Î Ȱ¿ëÇϱâ À§Çؼ­´Â ±¹Á¦º¸°Ç±â±¸¿ÍÀÇ Àü·«Àû ÆÄÆ®³Ê½ÊÀ» Ȱ¿ëÇϰí ÄݵåüÀÎ ÀÎÇÁ¶ó¿¡ ÅõÀÚÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ[2023] 6,434¸¸ ´Þ·¯
¿¹Ãø³â[2024] 8,088¸¸ ´Þ·¯
¿¹Ãø³â[2030] 3¾ï 2,066¸¸ ´Þ·¯
CAGR(%) 25.78%

¹é½Å ¹èÆ÷ÀÇ ¹°·ù Àå¾Ö¹°, ¿ø°ÝÁö¿¡¼­ÀÇ ÀÎ½Ä ºÎÁ·, ºÎÀÛ¿ë °¡´É¼º, ƯÈ÷ ÀÚ¿øÀÌ ºÎÁ·ÇÑ È¯°æ¿¡¼­ÀÇ ¹é½Å º¸°ü ¹®Á¦ µîÀÌ ÇѰè¿Í °úÁ¦·Î ²ÅÈü´Ï´Ù. ¶ÇÇÑ ÀÚ±Ý Á¶´ÞÀÇ ºÒÈ®½Ç¼º°ú ¹é½Å¿¡ ºÎºÐÀûÀ¸·Î ³»¼ºÀ» °¡Áø ¸»¶ó¸®¾Æ ±ÕÁÖÀÇ ÃâÇöÀº Ãß°¡ÀûÀÎ ¼ºÀåÀÇ À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ±â¼ú Çõ½ÅÀÇ ±âȸ´Â dzºÎÇϸç, ƯÈ÷ ´õ ³ÐÀº ¹üÀ§ÀÇ ±ÕÁÖ¸¦ Ä¿¹öÇϰí È¿´ÉÀ» °³¼±ÇÑ ¹é½ÅÀ» °³¹ßÇÏ´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù. ºñ¿ë È¿À²ÀûÀÎ Á¦Á¶ ¹æ¹ý°ú ´õ ½¬¿î Àü´ÞÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ´ÙÁß Ç÷§Æû ±â¼ú¿¡ ´ëÇÑ ¿¬±¸´Â »ç¾÷ ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©ÀÇ ±×´Ã¿¡¼­ ¹ßÀüÇÏ´Â ½ÃÀåÀº Áö¼Ó°¡´É¼º°ú Á¢±Ù¼ºÀÇ Çʿ伺¿¡ ÀÇÇØ Å©°Ô Á¿ìµÇ´Â ¸Å¿ì ¿ªµ¿ÀûÀÎ ½ÃÀåÀ¸·Î °è¼Ó ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ±â¾÷Àº Àú·ÅÇÑ °¡°ÝÀ» º¸ÀåÇÏ´Â Çù·Â ¸ðµ¨¿¡ ÃÊÁ¡À» ¸ÂÃß°í Àú¼Òµæ Áö¿ªÀÇ ¹°·ù ¹× À¯Åë È¿À²¼ºÀ» ³ôÀÌ´Â ±â¼ú ÁÖµµÇü ¼Ö·ç¼Ç¿¡ ¿ì¼±¼øÀ§¸¦ µÎ¾î¾ß ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® ÆÄ¾Ç

¸»¶ó¸®¾Æ ¹é½Å ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¿ªÀû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Á¤±â ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ ±ÞÁõ
    • ¸»¶ó¸®¾Æ ¹é½ÅÀÇ °¡¿ë¼º, Á¢±Ù¼º ¹× Á¤ºÎ Áö¿ø Áõ°¡
    • ¸»¶ó¸®¾Æ¿¡ ´ëÇÑ È¯ÀÚ ÀÎ½Ä ¹× ¹ß»ý·ü Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¹é½ÅÀÇ ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • »õ·Î¿î º¸Á¶Á¦ ¹× ȹ±âÀûÀÎ ¹é½Å Àü´Þ ÇÁ·Î±×·¥ÀÇ Áö¼ÓÀûÀÎ µîÀå
    • ¹é½Å °ü·Ã Á¦¾à¾÷°èÀÇ ¹ßÀüÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.
  • ½ÃÀå °úÁ¦
    • ¾ö°ÝÇÑ ±ÔÁ¦ ½Ã³ª¸®¿À

Portre's Five Forces: ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå °ø·«À» À§ÇÑ Àü·«Àû Åø

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå¿¡ ´ëÇÑ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

¸»¶ó¸®¾Æ ¹é½Å ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå¿¡¼­ÀÇ ¼º°øÀ» À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. :

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù. :

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÔ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå : À¯Çüº°

  • ÀûÇ÷±¸ ¹é½Å
  • ´ÙÇ׿ø ¹é½Å
  • ÀûÇ÷±¸Àü ¹é½Å

Á¦7Àå ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå : ¿¡ÀÌÀüÆ®º°

  • Anopheles Species
  • Plasmodium Falciparum
  • Plasmodium Vivax

Á¦8Àå ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • Ŭ¸®´Ð
  • Ä¿¹Â´ÏƼ ¼¾ÅÍ
  • º´¿ø

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Amyris, Inc.
  • Bharat Biotech International Limited
  • Cadila Healthcare Ltd.
  • CellFree Sciences Co.,Ltd.
  • GenVec, Inc.
  • GlaxoSmithKline PLC
  • Ipca Laboratories Limited
  • Merck & Co., Inc
  • Mymetics Corporation
  • Novartis AG
  • Novavax, Inc.
  • Precigen, Inc.
  • Sanaria Inc.
  • Sumaya Biotech
  • Sun Pharmaceutical Industries Limited
KSA 24.11.22

The Malaria Vaccine Market was valued at USD 64.34 million in 2023, expected to reach USD 80.88 million in 2024, and is projected to grow at a CAGR of 25.78%, to USD 320.66 million by 2030.

The malaria vaccine market is defined by its critical role in combating the malaria epidemic, particularly in malaria-endemic regions predominantly across Africa, Southeast Asia, and parts of Latin America. The necessity of a malaria vaccine is underscored by the persistent global health burden malaria poses, leading to significant morbidity and mortality. The primary application of malaria vaccines involves preventive inoculations to reduce infection rates and transmission, thus contributing to public health improvement and economic productivity in affected regions. Key end-users include government health bodies, non-governmental organizations, public health initiatives, and potentially private healthcare providers as distribution scales. Market insights indicate that factors such as increasing R&D investments, advancements in biotechnology, and global health partnerships are positively influencing market growth. Recent developments include WHO's approval of the RTS,S/AS01 (Mosquirix) vaccine, which presents significant opportunity for expansion into larger immunization programs. Leveraging strategic partnerships with international health agencies and investing in cold chain infrastructure are recommended to harness these opportunities effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 64.34 million
Estimated Year [2024] USD 80.88 million
Forecast Year [2030] USD 320.66 million
CAGR (%) 25.78%

Limitations and challenges include logistical hurdles in vaccine distribution, lack of awareness in remote areas, potential side effects, and vaccine storage issues, particularly in resource-limited settings. Moreover, funding uncertainties and the emergence of malaria strains with partial vaccine resistance pose additional growth barriers. However, opportunities for innovation abound, particularly in developing vaccines with broader strain coverage and improved efficacy. Research into cost-effective production methods and multi-platform technologies that facilitate easier delivery can drive business growth. The market, evolving under the shadow of stringent regulatory frameworks, remains highly dynamic and primarily driven by the need for sustainability and accessibility. Hence, companies must focus on collaborative models that ensure affordability and prioritize technology-driven solutions that enhance logistics and distribution efficiency in lower-income regions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Malaria Vaccine Market

The Malaria Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Proliferation in the number of routine immunizations programs
    • Rising availability, accessibility and favorable government support for malaria vaccine
    • Growing patient awareness and incidence of malaria
  • Market Restraints
    • High cost of the vaccines
  • Market Opportunities
    • Ongoing advent of novel adjuvants and breakthrough vaccine delivery programs
    • Rising advancements in pharmaceutical industry for vaccines
  • Market Challenges
    • Rigid regulative scenarios

Porter's Five Forces: A Strategic Tool for Navigating the Malaria Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Malaria Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Malaria Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Malaria Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Malaria Vaccine Market

A detailed market share analysis in the Malaria Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Malaria Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Malaria Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Malaria Vaccine Market

A strategic analysis of the Malaria Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Malaria Vaccine Market, highlighting leading vendors and their innovative profiles. These include Amyris, Inc., Bharat Biotech International Limited, Cadila Healthcare Ltd., CellFree Sciences Co.,Ltd., GenVec, Inc., GlaxoSmithKline PLC, Ipca Laboratories Limited, Merck & Co., Inc, Mymetics Corporation, Novartis AG, Novavax, Inc., Precigen, Inc., Sanaria Inc., Sumaya Biotech, and Sun Pharmaceutical Industries Limited.

Market Segmentation & Coverage

This research report categorizes the Malaria Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Erythrocytic Vaccine, Multi-Antigen Vaccine, and Pre-Erythrocytic Vaccine.
  • Based on Agent, market is studied across Anopheles Species, Plasmodium Falciparum, and Plasmodium Vivax.
  • Based on End-User, market is studied across Clinics, Community Centers, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Proliferation in the number of routine immunizations programs
      • 5.1.1.2. Rising availability, accessibility and favorable government support for malaria vaccine
      • 5.1.1.3. Growing patient awareness and incidence of malaria
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advent of novel adjuvants and breakthrough vaccine delivery programs
      • 5.1.3.2. Rising advancements in pharmaceutical industry for vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Rigid regulative scenarios
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Malaria Vaccine Market, by Type

  • 6.1. Introduction
  • 6.2. Erythrocytic Vaccine
  • 6.3. Multi-Antigen Vaccine
  • 6.4. Pre-Erythrocytic Vaccine

7. Malaria Vaccine Market, by Agent

  • 7.1. Introduction
  • 7.2. Anopheles Species
  • 7.3. Plasmodium Falciparum
  • 7.4. Plasmodium Vivax

8. Malaria Vaccine Market, by End-User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Community Centers
  • 8.4. Hospitals

9. Americas Malaria Vaccine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Malaria Vaccine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Malaria Vaccine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amyris, Inc.
  • 2. Bharat Biotech International Limited
  • 3. Cadila Healthcare Ltd.
  • 4. CellFree Sciences Co.,Ltd.
  • 5. GenVec, Inc.
  • 6. GlaxoSmithKline PLC
  • 7. Ipca Laboratories Limited
  • 8. Merck & Co., Inc
  • 9. Mymetics Corporation
  • 10. Novartis AG
  • 11. Novavax, Inc.
  • 12. Precigen, Inc.
  • 13. Sanaria Inc.
  • 14. Sumaya Biotech
  • 15. Sun Pharmaceutical Industries Limited
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦